Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

MicroRNA Studies to Be Enhanced by a New Line of Anti-miRNA Tools

By BiotechDaily International staff writers
Posted on 13 Feb 2014
Print article
Image: An artist's rendition of a Lentivirus expression vehicle (Photo courtesy of AMS Biotechnology ).
Image: An artist's rendition of a Lentivirus expression vehicle (Photo courtesy of AMS Biotechnology ).
A novel line of ready-to-use lentiviral expression vehicles provides microRNAs (miRNAs) and miRNA inhibitors for use as tools for the study of miRNAs and their role in various disease processes.

Lentiviruses, which are members of a subfamily of the retrovirus family, can deliver significant amounts of genetic information into host cells and integrate it into the cellular genome. Genetically engineered lentiviruses are therefore used as one of the most efficient tools of gene delivery. These modified lentiviruses contain a viral promoter that is used to control the expression of a transgene or shRNA but no residual virulence genes. Together with several other security modifications, this ensures their safe use in the laboratory.

MiRNAs comprise a family of small noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

Anti-miRNAs are miRNA inhibitors that are short RNA molecules complementary to the mature miRNA sequence. Anti-miRNA binds to endogenous miRNA and inhibits or down-regulates specific miRNAs. MiRNA inhibitors also show potential as therapeutic agents for some biological malfunctions.

AMS Biotechnology (Abingdon, United Kingdom) has introduced a range of ready-to-use human and mouse Lentivirus products for miRNA and anti-miRNA expression. This range of miRNA inhibitors was produced from optimally designed anti-miRNA lentivectors. AMS Biotechnology's anti-miRNA lentivectors were carefully designed for highest anti-miRNA expression levels with precise promoter transcription position, and to favor the antisense strand for RNA-induced silencing complex (RISC) processing.

Related Links:

AMS Biotechnology



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.